Streetbeat News

Partnerships

RSLS

ReShape Lifesciences has signed an exclusive license agreement with Biorad Medisys for the Obalon Gastric Balloon System, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:34 pm

FUV

Arcimoto has entered into a contract manufacturing agreement with MOBIUS.energy to build battery packs for the aviation market. Arcimoto will manufacture MOBIUS packs and integrate the technology into its production vehicles.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:34 pm

DXCM

Dexcom Canada, a subsidiary of Dexcom Inc. (DXCM), has partnered with RxFood Corporation to develop an AI-powered nutrition and glucose monitoring solution for diabetes management and personalized therapeutic nutrition.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:34 pm

AAPL

NVDA

TSM

Nvidia Corp (NVDA) stock is trading lower as the company strategizes to overcome supply constraints, U.S. semiconductor sanctions on China, and competition from Huawei. CEO Jensen Huang has been focusing on business opportunities in India, discussing the potential for the country to become a hub for AI talent, chip production, and a market for Nvidia's products. This comes as the U.S. tightens restrictions on exporting high-end chips to China. Meanwhile, Apple Inc's (AAPL) major suppliers in Taiwan saw a 12.3% drop in sales, and Taiwan Semiconductor Manufacturing Co (TSM) faced challenges in supplying Nvidia chips due to advanced packaging requirements.

Portfolio Pulse from Anusuya Lahiri

September 21, 2023 | 12:34 pm

RSLS

ReShape Lifesciences Inc. (NASDAQ:RSLS) has signed an exclusive, royalty-bearing license agreement with Biorad Medysis to manufacture, commercialize and distribute the Obalon Gastric Balloon System in South Asia. The agreement includes an upfront payment of $200,000 from Biorad to ReShape and ongoing license payments of 4% on gross sales of the Obalon Balloon System in the territories.

Portfolio Pulse from Happy Mohamed

September 21, 2023 | 12:32 pm

ORGS

Orgenesis Inc. (NASDAQ:ORGS) is expanding its cell and gene therapy development and patient access across the US through its subsidiary Octomera, in partnership with CGT Global. The collaboration aims to leverage CGT Global's network of CGT Clinics and healthcare partnerships to commercialize CGTs in California and other US locations. The companies plan to align resources to place Octomera Mobile Processing Units & Labs (OMPULs) for leukapheresis and the production of CAR-T and TILS products. The partnership is expected to grow as CGT Global currently partners with 32 hospitals and anticipates partnering with over 200 hospitals by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:20 pm

KAVL

PM

Kaival Brands has received its initial royalty payment from Philip Morris International due to increased international sales. This follows a recently amended agreement between the two companies.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:17 pm

BLNK

Blink Charging has partnered with Moberly Motor Company and Electric Era to bring fast and efficient DC charging to the dealership. This collaboration aims to provide a seamless charging experience for electric vehicle owners.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:16 pm

AVGO

Broadcom's shares are trading lower following a report by The Information suggesting that Google is considering dropping Broadcom as its AI chip supplier.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:13 pm

DARE

Daré Bioscience, Inc. (NASDAQ:DARE) will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of its investigational contraceptive DARE-LARC1. The total grant could reach up to $49 million. Daré received an initial $11.5 million payment in 2021 and aggregate payments of approximately $12.4 million in 2022. The company is also advancing the late-stage development of Ovaprene, a hormone-free monthly intravaginal contraceptive. Daré has a license agreement with Bayer for the development and commercialization of Ovaprene in the United States, if approved by the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 12:06 pm